Related Experiment Video
Updated: Sep 3, 2025

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease
Mingyue He1, Deping Wang2, Yumei Xu1
1Department of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China.
This review explores advanced biomaterial platforms for controlled nitric oxide (NO) delivery to treat cardiovascular disease (CVD). These platforms aim to overcome limitations of current NO prodrugs for improved CVD therapy.
Area of Science:
- Biomaterials Science
- Cardiovascular Medicine
- Pharmacology
Background:
- Cardiovascular disease (CVD) remains the leading global cause of mortality.
- Nitric oxide (NO) is crucial for cardiovascular function and a basis for CVD therapy.
- Current NO prodrugs suffer from low payload, burst release, and poor delivery control.
Purpose of the Study:
- To review recent advancements in biomaterial-based platforms for NO delivery in CVD treatment.
- To discuss strategies for enhancing NO therapy effectiveness.
Main Methods:
- Literature review of biomaterial platforms engineered for controlled NO release.
- Analysis of therapeutic strategies combining NO with hydrogen sulfide or stem cell therapy.
Main Results:
- Biomaterial platforms offer controlled and sustained NO delivery, addressing limitations of traditional prodrugs.
- Combination therapies show potential for synergistic effects in CVD treatment.
Conclusions:
- Engineered NO-releasing platforms hold promise for improved CVD therapeutics.
- Integrating NO therapy with hydrogen sulfide or stem cell approaches may enhance treatment efficacy.
More Related Videos
08:58En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
08:32Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
Related Concept Videos
Nitric Oxide Signaling Pathway
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...